Extract from the Clinical Evaluation Report for Human ...

Protocol V503-009(Study 009) provided immunological bridging from qHPV vaccine to 9vHPV vaccine in preadolescent and adolescent girls, 9 to 15 years of age, by demonstrating that both vaccines have similar immunogenicity with respect to HPV 6, 11, 16, and 18. ... Subject is judged to be in good physical health on the basis of medical history ... ................
................